This site is intended for health professionals only

Saturday 19 October 2019

Heerajnarain Bulluck PhD MRCP

Articles by this author

Tue 11 September
Tue 11 September
The development of PCSK9 inhibitors is a great example of serendipity, clever exploitation of a fascinating genetic observation, and rational drug development using monoclonal antibody technology in the 21st century